Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.
about
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerThe SUMO conjugating enzyme UBC9 as a biomarker for cervical HPV infections.A monoclonal antibody against the human SUMO-1 protein obtained by immunization with recombinant protein and CpG-DNA-liposome complex.Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening.SUMO pathway components as possible cancer biomarkers.Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin.
P2860
Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Association of SUMO1 and UBC9 ...... irinotecan-based chemotherapy.
@en
Association of SUMO1 and UBC9 ...... irinotecan-based chemotherapy.
@nl
type
label
Association of SUMO1 and UBC9 ...... irinotecan-based chemotherapy.
@en
Association of SUMO1 and UBC9 ...... irinotecan-based chemotherapy.
@nl
prefLabel
Association of SUMO1 and UBC9 ...... irinotecan-based chemotherapy.
@en
Association of SUMO1 and UBC9 ...... irinotecan-based chemotherapy.
@nl
P2093
P2860
P356
P1476
Association of SUMO1 and UBC9 ...... irinotecan-based chemotherapy.
@en
P2093
Eun Young Cho
Geon Kook Lee
Heung Tae Kim
Ji-Youn Han
Jin Soo Lee
Sun Young Yoo
Sung Jin Yoon
P2860
P2888
P356
10.1038/TPJ.2009.46
P577
2009-10-27T00:00:00Z